搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Lysosomal acid lipase/cholesteryl ester hydrolase(LIPA) ELISA kit

Human Lysosomal acid lipase/cholesteryl ester hydrolase(LIPA) ELISA kit

  • 中文名稱：
    人溶酶體酸性脂肪酶/膽固醇酯水解酶(LIPA)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-EL012972HU
  • 規(guī)格：
    96T/48T
  • 價格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人溶酶體酸性脂肪酶/膽固醇酯水解酶(LIPA)酶聯(lián)免疫試劑盒（CSB-EL012972HU）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、組織勻漿、細胞裂解物樣本中的LIPA含量。LIPA 即溶酶體酸性脂肪酶，它在脂質(zhì)代謝中起關鍵作用。當 LIPA 功能缺陷時會引發(fā)膽固醇酯和甘油三酯在溶酶體內(nèi)蓄積。目前研究聚焦其參與脂質(zhì)代謝的機制，探索通過調(diào)節(jié)它來改善脂質(zhì)代謝紊亂相關疾病。試劑盒檢測范圍為62.5 pg/mL-4000 pg/mL，該產(chǎn)品可用于體外研究LIPA在脂質(zhì)代謝調(diào)控中的生物學功能，適用于細胞模型中酶活性相關基因調(diào)控實驗、動物疾病模型的組織表達水平分析，或藥物干預下LIPA表達變化的動態(tài)監(jiān)測，為脂代謝相關疾病的分子機制研究及潛在治療靶點開發(fā)提供可靠工具。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名：
    Acid cholesteryl ester hydrolase ELISA Kit; CESD ELISA Kit; cholesterol ester hydrolase ELISA Kit; cholesterol ester storage disease ELISA Kit; Cholesteryl esterase ELISA Kit; Hydrolase deficiency ELISA Kit; LAL ELISA Kit; LAL deficiency cholesterol ester ELISA Kit; LICH_HUMAN ELISA Kit; lipA ELISA Kit; LIPA deficiency ELISA Kit; Lipase A ELISA Kit; lipase A; lysosomal acid; cholesterol esterase ELISA Kit; lysosomal acid lipase ELISA Kit; lysosomal acid lipase deficiency ELISA Kit; Lysosomal acid lipase/cholesteryl ester hydrolase ELISA Kit; Sterol esterase ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates, cell lysates
  • 檢測范圍：
    62.5 pg/mL-4000 pg/mL
  • 靈敏度：
    15.6 pg/mL
  • 反應時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領域：
    Metabolism
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human LIPA in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    SampleSerum(n=4)
    1:1Average %87
    Range %82-90
    1:2Average %105
    Range %101-09
    1:4Average %88
    Range %85-91
    1:8Average %94
    Range %91-99
  • 回收率：
    The recovery of human LIPA spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 8682-90
    EDTA plasma (n=4)9490-100
  • 標準曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/mlOD1OD2AverageCorrected
    40002.142 2.168 2.155 2.023
    20001.851 1.732 1.792 1.660
    10001.264 1.297 1.281 1.149
    5000.898 0.887 0.893 0.761
    2500.563 0.598 0.581 0.449
    1250.352 0.346 0.349 0.217
    62.50.201 0.206 0.204 0.072
    00.131 0.133 0.132
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價

靶點詳情

  • 功能：
    Catalyzes the deacylation of triacylglyceryl and cholesteryl ester core lipids of endocytosed low density lipoproteins to generate free fatty acids and cholesterol.
  • 基因功能參考文獻：
    1. Report LIPA variants/phenotype in childhood-onset lysosomal acid lipase deficiency. PMID: 28881270
    2. LAL activity is significantly reduced in NAFLD, compared to that in HCV patients. This finding is particularly evident in the pre-cirrhotic stage of disease. LAL activity is also correlated with platelet and white blood cell count, suggesting an analytic interference of portal-hypertension-induced pancytopenia on DBS-determined LAL activity. PMID: 28587063
    3. LAL plays a critical role in regulating mesenchymal stem cells' ability to stimulate tumor growth and metastasis, which provides a mechanistic basis for targeting LAL in MSCs to reduce the risk of cancer metastasis PMID: 27531897
    4. Report a marked reduction of LAL activity in patients with cryptogenic cirrhosis. PMID: 28396038
    5. LIPA mutations may have a role in with a clinical diagnosis of familial hypercholesterolemia PMID: 27423329
    6. Use CRISPR/Cas9 techniques to knockout LIPA in human induced pluripotent stem cells and differentiate them to macrophages. PMID: 28882870
    7. LIPA associated with Familial Hypercholesterolemia and Polygenic Hypercholesterolemia in patients with Acute Coronary Syndrome , age /=160 mg/dl. PMID: 28958330
    8. Study demonstrates that liver cirrhosis from any etiology is characterized by a significant reduction of LAL activity but no known c.894G>A SNP, which is likely on an acquired base and independent from the etiology of hepatic disease. PMID: 27219619
    9. Coronary artery disease-associated coding variant rs1051338 causes reduced lysosomal LAL protein and activity because of increased LAL degradation. PMID: 28279971
    10. results indicate that LAL is the major acid RE hydrolase and required for functional retinoid homeostasis. PMID: 27354281
    11. These findings suggest a strong association between impaired LAL activity and Non-alcoholic fatty liver disease. PMID: 26288848
    12. lysosomal acid lipase in hepatocytes is a critical metabolic enzyme in controlling neutral lipid metabolism PMID: 26212911
    13. The observed loss-of-function phenotype in cholesteryl ester storage disease patients with the His295Tyr (H295Y) mutation in the LAL gene might arise from a combination of protein destabilization and the shift to a non-functional soluble aggregate. PMID: 25620107
    14. Case Report: Mexican sisters with heterozygous mutations in exon 4: c.253C>A and c.294C>G resulting in lysosomal acid lipase deficiency. PMID: 25624737
    15. Wolmans disease is a rare autosomal recessive lysosomal storage disease. PMID: 24832708
    16. To our knowledge, this is the first pediatric case of genetically and biopsy confirmed CESD without hepatomegaly, suggesting that this diagnosis can be easily missed. PMID: 24122380
    17. the rs1412444 and rs2246833 of the LIPA gene are shared susceptibility polymorphisms for CAD among different ethnicities. PMID: 24069331
    18. used (1)H magnetic resonance (MR) spectroscopy to characterize the abnormalities in hepatic lipid content and composition in patients with LAL deficiency PMID: 23624251
    19. The results show that lysosomal acid lipase E8SJM mutation carriers have an alteration in lipid profile with a Polygenic Hypercholesterolemia phenotype. PMID: 22795295
    20. CESD prevalence in African and Asian populations may require full-gene LIPA sequencing to determine heterozygote frequencies. CESD may be underdiagnosed in the general Caucasian and Hispanic populations. PMID: 23424026
    21. Mutations in lysosomal acid lipase A result in two phenotypes depending on the extent of lysosomal acid lipase deficiency. [Review] PMID: 23652569
    22. The expression of LIPA may be associated with increased phospholipid content in the brains of violent suicide completers. PMID: 23164340
    23. LIPA polymorphisms contribute to the interindividual variability observed in obesity-related metabolic complications PMID: 22395809
    24. study identified two novel mutations of LIPA gene in Wolman Disease patients which abolished the expression of LAL enzyme; also found that all cholesteryl ester storage disease patients carried the common mutant allele c.894G>A PMID: 22227072
    25. a novel paternally inherited c.482delA mutation in exon 5 of Lipase A that results in a frameshift mutation at amino acid 161 is reported in a fatal case of Wolman disease PMID: 21963785
    26. Lysosomal acid lipase in myeloid cells plays a critical role in maintaining normal hematopoietic cell development and balancing immunosuppression and inflammation. PMID: 21900179
    27. macrophage cholesteryl ester hydrolase associates with its intracellular substrate (lipid droplets) and hydrolyzes cholesteryl esters more efficiently from mixed droplets PMID: 16024911
    28. The human liver enzyme is expressed in hepatocytes, where it potentially regulates the synthesis of bile acids and thus the removal of cholesterol from the body. PMID: 16131527
    29. Although LAL contributed to the deesterification of DHEA-FAE, it was not solely responsible for the hydrolysis. PMID: 18796546
    30. the molecular characterization of three heterozygous patients with Cholesteryl Ester Storage Disease carrying the common LIPA gene mutation (c.894 G>A, del p.S275_Q298), in combination with two novel mutations resulting in null alleles, was reported. PMID: 19307143

    顯示更多

    收起更多

  • 相關疾?。?/div>
    Wolman disease (WOD); Cholesteryl ester storage disease (CESD)
  • 亞細胞定位：
    Lysosome.
  • 蛋白家族：
    AB hydrolase superfamily, Lipase family
  • 組織特異性：
    Most abundantly expressed in brain, lung, kidney and mammary gland, a moderate expression seen in placenta and expressed at low levels in the liver and heart.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 6617

    OMIM: 278000

    KEGG: hsa:3988

    STRING: 9606.ENSP00000337354

    UniGene: Hs.643030